1 minute read

Phaim Pharma

Next Article
Oribiotech

Oribiotech

www.phaim.co.uk www.linkedin.com/company/phaimpharma/

Phaim is developing novel therapies for the treatment and early detection of autoimmune disease with a lead product in Type1 Diabetes. Phaim’s platform approach to autoimmunity will recapitulate the normal regulatory immune response, preventing the onset of T1DM in prediabetics, and facilitating the use of cellular therapies in the treatment of established T1DM patients.

Advertisement

The platform has means of identifying targets in other autoimmune diseases, such as psoriasis and we would look to produce other therapies after our successful T1DM trial. Furthermore, with our proprietary diagnostic kit, we will be able to predict who is likely to get T1DM and in what time frame.

By doing so, we could potentially treat before the disease develops and look to ameliorate the need for insulin. In short, Phaim can predict, prevent and potentially treat type 1 diabetes and other autoimmune conditions. Phaim’s T1D therapy alone has a potential of world-wide market capture.

Phaim Pharma is dedicated to developing curative treatments for autoimmune disease affecting 5-10% of the global population. It is both a platform and a product company, producing assets for sale or licensing in individual autoimmune diseases with a lead drug in type 1 diabetes.

Dr. Nara Daubeney Chief Operating Officer and Co-Founder

+44 207 351 7011 nara.daubeney@phaim.co.uk

Professor Piers Daubeney Chief Business Officer

piers.daubeney@phaim.co.uk

This article is from: